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Abstract: The pulse wave velocity (PWV), as an indicator of arterial distensibility, may play an important role in the 
stratification of patients based on the cardiovascular risk. PWV inversely correlates with arterial distensibility and relative 
arterial  compliance.  Decreased
  arterial  distensibility  alters  arterial  blood  pressure
  and  flow  dynamics,  and  disturbes  
coronary perfusion. Systemic immune and inflammatory diseases, such as rheumatoid arthritis (RA) and systemic lupus 
erythematosus (SLE) are associated with increased morbidity and mortality, predominantly due to adverse cardiovascular 
events. Systemic inflammation in these disorders may alter arterial compliance and arterial distensibility and, through this 
effect, lead to accelerated atherosclerosis. We have demonstrated an increase in the carotid-femoral (aortic) PWV that is a 
technique in which large artery elasticity is assessed from analysis of the peripheral arterial waveform, in patients with 
chronic  inflammatory  conditions  such  as  RA,  SLE,  familial  Mediterranean  fever  (FMF),  Wegener’s  granulomatosis 
(WG),  sarcoidosis, psoriasis  and psoriatic  arthritis except Behçet’s disease (BD).  In this review,  the  issue of arterial  
stiffness in RA, SLE, as well as WG, psoriasis, FMF, BD, sarcoidosis, systemic sclerosis (SS) and Takayasu's arteritis 
(TA) is overviewed. 
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INTRODUCTION 
  Systemic  immune  and  inflammatory  diseases,  such  as 
rheumatoid arthritis (RA) and systemic lupus erythematosus 
(SLE) are associated with increased morbidity and mortality 
[1, 2]. Most of this increased mortality is attributable to car-
diovascular events [1, 2]. Endothelial dysfunction, character-
ized by reduced nitric oxide bioavailability, is an early stage 
in the pathogenesis of atherosclerosis. Inflammation is asso-
ciated with endothelial dysfunction and atherosclerosis [3]. 
Damage  to  the  arterial  wall  due  to  atherosclerosis  causes 
increased arterial stiffness. Atherosclerosis and its effects on 
the arterial system may be measured noninvasively by some 
techniques [4, 5]. One such technique, pulse wave velocity 
(PWV), which is defined as arterial pulse’s velocity of mov-
ing along vessel wall, as an indicator of arterial distensibil-
ity,  plays  an  important  clinical  role  in  describing  patients 
under high cardiovascular risk and serebrovascular risk [4]. 
PWV is inversely correlated with arterial distensibility and 
relative arterial compliance. Theoretically, the wave velocity 
(C0), in a thin-walled, uniform, elastic vessel containing an 
incompressible, inviscous fluid, with no reflections, can be 
expressed  by  the  Moens-Korteweg  equation  [6,  7]:  C0  = 
√Eh/2ρR (E: Young’s modulus of elasticity, h: wall thick-
ness, R: mean radius, ρ: blood density). Following Bramwell 
and  Hill  [8],  equation  of  Moens-Korteweg  also  can  be  
expressed as C0 = √dP V/dV ρ (P: pressure, V: volume of 
tube  per  unit  length,  dV/VdP:  volume  compliance  of  the 
tube). In  this  equation,  the square of the wave velocity is 
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associated with the inverse of the volume compliance  that 
represents the total arterial stiffness. 
  Arterial stiffness increases in  accelerated atherosclerosis 
due to inflammation [9]. Large artery stiffness is recognized 
as a modifiable, independent predictor of cardiovascular risk 
[10]. Structural components within the arterial wall, mainly 
collagen and elastin, together with transmural pressure, are 
key  determinants  of  large  arterial  PWV.  Arterial  stiffness 
can  be  affected  by  both  structural  and  functional  changes 
[11]. Structural changes involve the composition of the arte-
rial wall, hypertrophy of smooth muscle cell and decrease in 
contents of extracellular matrix [12]. Endothelial dysfunction 
leads  to  a  number  of  changes  in  the  extracellular  matrix  
including  smooth  muscle  cell  proliferation  and  increased 
synthesis of structural proteins including collagen [13, 14]. 
An increase in circulating inflammatory mediators promotes 
white cell infiltration into arteries, and a change in vascular 
smooth muscle phenotype. Both these cell types release the 
matrix metalloproteinases that can degrade elastin. Decrease 
of  elastin  from  the  media  could  be  expected  to  result  in  
arterial stiffening. Under inflammatory conditions, vascular 
smooth muscle cells also express osteoblast markers and can 
take up phosphate to produce bioapatite, leading to medial 
calcification and reduced arterial distensibility. Perivascular 
inflammation  and  cellular  infiltration  around  the  vasa 
vasorum  may  lead  to  vessel  ischemia,  which  may  also  
promote matrix remodeling and eventually stiffening of the 
arteries.  The  increase  in  aortic  stiffness  may  increase  the 
impedance  to  left  ventricular  ejection  and  then  reduce  the 
effective coronary blood flow: The arterial pressure wave-
form is a composite of the forward
 pressure wave created 
by ventricular  contraction and  a reflected
 wave. In  elastic 
vessels such as aorta, the
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at the aortic root during
 diastole, serving to augment diastolic 
blood  pressure  and  therefore,  improve
  coronary  artery  
perfusion [15]. In the case of stiff arteries the
 reflected wave 
arrives back at the central arteries earlier,
 causing augmenta-
tion  of  the  systolic  blood  pressure.  High  central  systolic 
blood pressure
  causes  the  development  of  left  ventricular 
hypertrophy  and  finally  reduces  coronary  artery  perfusion 
[15]. 
  Arteries become wider and less elastic (increased PWV) 
with advancing age as a consequence of the age-related re-
duction  in  arterial  elastin  and  increase in collagen content 
[16]. Stiffness becomes higher at high blood pressure  and 
lower at low blood pressure, through mechanical change in 
arterial wall stretching and resulting change in contribution 
of elastin and collagen fibers to the elastic modulus [17, 18]. 
However, smooth muscle tone also influences the stiffness of 
elastic  and muscular arteries, suggesting functional regula-
tion  of  stiffness  by  local  and/or  circulating  vasoactive  
substances such as endothelial derived nitric oxide [19-22]. 
This may explain why traditional risk factors such as hyper-
cholesterolemia  and  diabetes  mellitus,  which  are  known  
to  cause  endothelial  dysfunction  characterized  by  reduced 
nitric  oxide  bioavailability,  are  also  associated  with  
increased arterial stiffness.  
  Systemic  inflammation  has  been  associated  with  endo-
thelial  dysfunction  [23].  The  circulating  inflammation  
mediators  such as  C reactive protein (CRP) and cytokines 
can directly alter endothelial nitric oxide bioavailability. The 
degree of inflammation, as assessed by high sensitivity CRP, 
cytokines or antineutrophil cytoplasmic antibodies (ANCA) 
also  predicts  cardiovascular  mortality  and  morbidity  [1]. 
These observations suggest that arterial stiffness and cardio-
vascular  mortality  and  morbidity  should  be  increased  in  
subjects  with  systemic  inflammation  [24-34].  However, 
some  data  concerning  this  are  conflicting  [35].  We  and  
others have demonstrated an increase in the carotid-femoral 
(aortic)  PWV  that  is  a  technique  in  which  large  artery  
elasticity is assessed from analysis of the peripheral arterial 
waveform [4], in patients with chronic inflammatory condi-
tions such as RA, SLE, FMF, WG, sarcoidosis, psoriasis and 
psoriatic arthritis.  
The  Carotid-Femoral  (Aortic)  PWV  Measurement  in 
Different Inflammatory Disorders 
  In our study arterial stiffness was assessed by automatic 
carotid-femoral (aortic) PWV measurement using the Com-
plior Colson device (Createch Industrie, France); the techni-
cal characteristics of  this device have been described,  and 
indicate inter and intra observer repeatability coefficient val-
ues >0.9 [4]. The Complior system is designed to determine 
the arterial distensibility from the pulse wave time interval 
and velocity measurements. This system is made of a Com-
plior PC board installed in an IBM APTIVA. The Complior 
software takes use of the computer resources for the calcula-
tion, the display and the recording of the data. Two acoustic 
sensors deliver the signals of the pulse wave to the acquisi-
tion board. A pedal triggers the data acquisition. The Com-
plior kit is made of; (I) a Complior data acquisition board 
installed in an APTIVA IBM PC computer; the PC runs with 
a 486DX2 50MHz and has  a 270  Mo hard drive, (II) the 
Complior software version 3.0 installed in the IBM PC, (III) 
two acoustic sensors, (IV) a trigger pedal, (V) and a Cannon 
BJ-200ex printer. The computer is configured for 220V AC 
main. PWV along the aorta can be measured by using two 
ultrasound or strain-gauge transducers [non - invasively us-
ing a TY-306 Fukuda pressure sensitive transducer (Fukuda, 
Tokyo, Japan)] fixed transcutaneously over the course of a 
pair of arteries separated by a known distance: the femoral 
and  right  common  carotid  arteries.  During  preprocessing 
analysis the gain of each waveform was adjusted to obtain an 
equal signal for the two wave forms. During PWV measure-
ments, after pulse waveforms of sufficient quality were re-
corded, the digitalization process was initiated by the opera-
tor and automatic calculation of the time delay between two 
upstrokes was  started.  Measurement was repeated over 10 
different cardiac cycles, and the mean value was used for the 
final  analysis.  PWV  is  calculated  from  measurements  of 
pulse transit time and the distance (the distance between two 
recording sites is measured on the surface of body in meters) 
travelled by the pulse between two recording sites, according 
to the following formula:  
  PWV (m/s) = distance (m) / transit time (s) 
RA 
  RA is a systemic immune and inflammatory disease as-
sociated with accelerated atherosclerosis and excess cardio-
vascular morbidity and mortality [1, 36]. This inflammation 
may act to impair endothelial function, arterial compliance 
and  arterial  elasticity  and  as  a  contributing  factor  in  the  
initiation or the progression of atherosclerosis. Some studies 
showed that arterial elasticity is reduced in patients with RA 
[37, 38]. Recently, we also found that carotid-femoral PWV 
(8.29 ± 0.64 m/s vs 7.52 ± 0.63 m/s) is increased, arterial 
elasticity  is  decreased,  in  young  patients  with  RA  (21-34 
years  old,  7  women,  mean  RA  duration:  13.8  ±  12.6 
months),  as  compared  with  control  (p=0.03)  [27].  In  the 
young patients with RA pulse wave propagation time (it is 
inversely related to the arterial PWV to the classical formula 
“PWV (m/s)=Distance (m)/Transit time (s)”) between meas-
urement  sites  was  significantly  shorter  than  in  the  control 
group (p=0.02) [27].  
SLE 
  SLE  is  a  chronic  inflammatory  autoimmune
  disease  
affecting young women associated with increased atheroscle-
rotic vascular diseases [39]. In SLE, the degree of systemic 
inflammation correlates with development of atherosclerosis 
[40]. Antiphospholipid antibodies (aPL) (a family of autoan-
tibodies that recognize various combinations of phospholip-
ids  and  phospholipid-binding  proteins)  and  immune  com-
plexes occur more commonly in patients with SLE [41]. In 
SLE, although Farzaneh-Far et al. [42] suggest that aPL are 
not associated with increased preclinical or clinical athero-
sclerosis and arterial stiffening,  these  antibodies may be  a 
cause of arterial damage which initiates atherogenesis [39]. 
These  complexes  bind  to  receptors  on  the  endothelium,  
triggering  an  upregulation  of  adhesion  molecules  such  as  
E-selectin,  intercellular  adhesion  molecules  1  (ICAM-1)  
and  vascular  cell  adhesion  molecules  1  (VCAM-1).  Also, 
oxidized  low  density  lipoprotein  (LDL),  lipoprotein  (a)  
and CD40-CD40L have role in the pathogenesis of athero-
sclerosis,  thrombosis  and  inflammatory  processes  [43-46]. Arterial Distensibility in Chronic Inflammatory Rheumatic Disorders  The Open Cardiovascular Medicine Journal, 2010, Volume 4    85 
Recently, we found that carotid-femoral (aortic) PWV (8.98 
± 2.05 m/s vs 8.05 ± 0.94 m/s) is increased in premenopausal 
women with SLE (mean age: 33.6±9.6 vs 30.2±9.2 years old, 
24 women, mean SLE duration: 5.3 ± 4.6 years), as com-
pared  with  control  (p=0.04)  [28].  Aortic  PWV  was  deter-
mined by using an automatic device, the Complior Colson 
(France), which allowed on-line pulse wave recording and 
automatic calculation of PWV. 
WG 
  WG is a rare disease, affecting only 1 in every 30.000-
50.000 people, that often begins  with inflammation of the 
upper airways or lungs and may progress to an inflammation 
of  blood  vessels  throughout  the  body  [47-51].  There  is  a 
strong and specific association of WG with presence of anti-
neutrophil  cytoplasmic  antibodies  (ANCA)  to  a  defined  
target antigen, proteinase 3 (PR3-ANCA), which is present 
within  primary  azurophil  granules  of  neutrophils  and 
lysozymes  of  monocytes  [48].  Upon  cytokine  priming  of 
neutrophils,  this  enzyme  translocates  to  the  cell  surface, 
where PR3-ANCAs can interact with their antigens and acti-
vate neutrophils [49]. The presence of ANCA in the plasma 
of patients and genetic involvement of the human leukocyte 
antigen  system  reflects  an  autoimmune  background  of  the 
disease. de Leeuw et al. [52] demonstrated that atherosclero-
sis,  a  systemic  inflammatory  disease,  as  determined  by  
carotid  intima-media  thickness,  was  increased  in  patients 
with WG. Recently, we showed that carotid-femoral (aortic) 
PWV is increased in patients with WG, as compared with 
control (p=0.04) [29]. 
Psoriasis 
  Psoriasis is a hereditary and chronic inflammatory skin 
disorder  affecting  2-3%  of  the  Caucasian  population  [53].  
It is mediated by T cells, dendritic cells and inflammatory 
cytokines and characterized by marked increases in keratino-
cyte proliferation, prominent alterations in dermal capillary 
vasculature [54]. Psoriatic arthritis has been defined  as  an 
inflammatory  arthritis  associated  with  psoriasis,  usually 
seronegative for rheumatoid factor. Psoriatic arthritis affects 
men and women almost equally. The prevalence of Psoriatic 
arthritis among patients with psoriasis has varied from 6% to 
42%  [55].  It  is  demonstrated  that  psoriasis  and  psoriatic  
arthritis appear to be associated with an increased cardiovas-
cular  mortality  and  morbidity  [56].  We  and  others  have 
demonstrated  an  increase  in  the  carotid-femoral  (aortic) 
PWV [30, 57]. 
FMF 
  FMF  is  an  autosomal  recessive  disorder  virtually  re-
stricted to certain ethnic groups originating from the Middle 
East: Sephardic Jews, Armenians, Arabs, Druze and Turks 
[58]. It is characterized by recurrent episodes of serosal in-
flammation, chest pain, and arthritis usually accompanied by 
fever [58]. The main complication of untreated patients is the 
development  of  amyloidosis  [58].  In  most  FMF  patients, 
colchicine  treatment  prevents  febrile  attacks  and  develop-
ment  of  amyloidosis  [59].  During  the  febrile  attacks,  an 
acute  phase  response  develop,  manifested  by  a  marked  
increase  in  erythrocyte  sedimentation  rate  (ESR),  CRP,  
serum amyloid A, fibrinogen and leucocytes [58]. Histopa-
thologic  examination  of  FMF  involves  inflammation  with 
infiltration  by  neutrophils  [58].  In  our  study,  the  carotid-
femoral PWV (8.53±1.65 m/s vs 7.75±0.86 m/s) is slightly 
increased in patients with FMF which compared with control 
group  (p=0.05)  [31,  32].  We  found  significant  correlation 
between PWV and age (p<0.001, r=0.67), body mass index 
(p<0.001, r=0.52)  and leukocytes (p<0.001, r=0.66) in all 
groups and in patients with FMF group (p<0.001, r=0.73; 
p=0.01, r=0.52; p<0.001, r=0.69, respectively).  
  We found significant correlation between PWV and leu-
kocytes. FMF is an autosomal recessive disorder character-
ized by mutations in the MEFV gene located on 16p [60]. 
The  gene  encodes  a  781-amino  acid  protein  called  pyrin  
expressed in cells of the myeloid lineage. Although the role 
of MEFV gene in the development of FMF attacks does not 
yet  known  clearly,  its  malfunction  results  eventually  in  
inflammation.  And  it  has  been  proposed  that  in  FMF  
any minor stimulus leads to  an uncontrolled inflammatory 
reaction with complement activation, due to absence of an 
inhibitor of C5a
 and excessive tumor necrosis factor (TNF) 
release [61, 62]. The inflammatory process of FMF is also 
caused by leukotriene B4, a potent lipid chemoattractant and 
mediator of acute inflammation [63]. Circulating leucocytes 
play important roles in atherosclerosis which is an inflamma-
tory disease [64]. Positive associations between total leuko-
cyte  count  and  risk  factors  of  atherosclerosis  or  coronary 
artery diseases are frequently mentioned [65, 66].  
Sarcoidosis 
  Sarcoidosis  is a  systemic  inflammatory multiorgan dis-
ease, characterized in the affected organs by T-lymphocyte-
mononuclear  phagocyte  infiltration,  granuloma  formation, 
and  distortion  of  normal  microarchitecture.
  Histology  of 
granulomas shows a central zone with macrophages,
 epithe-
lioid cells, and multinucleated giant cells in addition
 to acti-
vated CD4 lymphocytes, and a peripheral zone with macro-
phages,
 fibroblasts, CD4 and CD8 lymphocytes [67-71]. The 
reported prevalence of sarcoidosis varies from 9 to 64 per 
100.000 populations (in Sweden and in Italy, respectively) 
[68].  Although,  sarcoidosis  is  known  to  be  a  systemic  
inflammatory  disease  which  can  affect  virtually
  any  organ 
system,  it  unusually  complicates  vascular  involvement. 
However in fact,
 several authors have suggested that vascu-
litis may be a feature
 of sarcoidosis; but, such reports usually 
related to cutaneous
 vasculitis [3, 4]. In a one study, granu-
lomatous  angiitis  and  microangiopathy  were  reported  in 
30.8%  of  sarcoidosis  patients  with  cutaneous  involvement 
[69]. On the other hand, reports on the coexistence of sarcoi-
dosis and vasculitis had led us to think the possibility that 
sarcoidosis and vasculitis may be etiopathgenetically related. 
This inflammation of sarcoidosis may act to impair endothe-
lial function, arterial compliance and arterial elasticity and as 
a contributing factor in the initiation or the progression of 
atherosclerosis. Recently, we demonstrated that the carotid-
femoral  (aortic)  PWV  (10.04±1.73  vs  9.05±1.18  m/s)  was 
higher  in  patients  with  sarcoidosis  (12  women,  7  man,  
sarcoidosis duration: 124.8 ± 85.9 months) than in control 
subjects (p=0.04) [33].  
BD 
  BD is a chronic, multisystem disorder characterized by 
genital and oral aphtae, skin lesions and uveitis [72]. In some 86    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Mustafa Yildiz 
patients,  manifestations  of  vascular  complications,  which 
may  include  deep  vein  and  arterial  thrombosis,  aortic  and 
arterial  aneurysm,  may  dominate  the  clinical  picture  [72]. 
The cause of vascular disease in BD is unknown. Histopa-
thologic  studies  have  demonstrated  that  the  predominant 
lesion is vasculitis. The vessel wall and perivascular tissue 
are infiltrated by lymphocytes, monocytes, plasma cells and 
neutrophils [72]. Recent studies suggest that activated leuko-
cytes may contribute to vascular injury in BD [73]. In vivo, 
neutrophils from patients with  BD generate high  levels of 
oxygen derived free radicals and cause endothelial cell lysis 
[73]. Concentrations of circulating lipid peroxidation prod-
ucts are elevated in patients with BD [74]. Orem et al. [75] 
studied plasma lipoprotein (a) and its relationship with dis-
ease activity in patients with BD. They concluded that the 
fluctuations of plasma lipoprotein levels with the activity of 
disease may be a contributing risk factor in the development 
of thrombogenic complications in patients with BD. Other 
study showed that the levels of autoantibodies against oxi-
dized LDL were significantly higher in patients than controls 
[76]. These autoantibodies may be a factor responsible for 
endothelial dysfunction and development of vascular pathol-
ogy in BD [76]. Lipid peroxidation was found increased in 
the  active  period  compared  to  the  inactive  period  of  BD. 
Therefore, patients with active BD may be much more sus-
ceptible to the atherogenic events than those in the inactive 
period  of  the  disease  and  control  subjects.  We  studied  14 
patients with BD (18-44 years old, 10 men) and 28 healthy 
subjects (18-39 years old, 21 men) without known cardio-
vascular  disease.  Arterial  distensibility  was  assessed  by 
automatic  carotid-femoral  PWV  measurement  using  the 
Complior Colson device. The carotid-femoral PWV (8.4±1.4 
vs 8.5±1.1 m/s) is not increased in patients with BD com-
pared with control subjects (p>0.05) [35]. This finding may 
explain the decrease of mortality rate within time in patients 
with BD. In contrast to our study Chang et al. [77] showed 
that patients with BD had significantly higher PWV values 
than in controls. 
SS 
  SS  is  a  clinically  heterogeneous  generalized  disorder 
which affects the connective tissue of the skin and internal 
organs  such  as  gastrointestinal  tract,  lungs,  heart  and  
kidneys. It is characterized by alterations of the microvascu-
lature, disturbances of the immune system and by massive 
deposition  of  collagen  [78].  Endothelial  dysfunction  and 
vasculopathy  of  the  small  and  large  vessels  are  crucial 
pathogenic  factors  in  SS.  Timár  et  al.  [79]  showed  that  
increased augmentation index, is used as clinical measure-
ments of arterial stiffness, and PWV of the aorta in compari-
son to age and sex matched healthy controls in patients with 
SS. Cypiene et al. [80] also demonstrated that SS patients 
have  increased  augmentation  index  and  PWV  and  lower 
flow-mediated  dilatation  (is  an  ultrasound-based  technique 
that  measures  nitric  oxide  mediated  vasodilatation  of  the 
brachial artery  in response to increased  arterial wall shear 
stress) as compared to control subjects.  
TA 
  TA is a rare, chronic, inflammatory disease primarily of 
the aorta and its branches [81, 82]. The subclavian, renal and 
carotid arteries can also be involved. Inflammation of large 
blood vessels may cause segments of the vessels to weaken 
and stretch, resulting in an aneurysm. Vessels can also be-
come  narrowed  or  even  completely  blocked.  TA  is  more 
common in women than in men and usually begins in the 2
nd 
or 3
rd decade [82]. The diagnosis of TA is based on a combi-
nation  of  factors,  including  angiography,  computed  axial 
tomography and magnetic resonance imaging. Cardiovascu-
lar disease  is a  major cause of mortality and morbidity  in 
patients with TA. Ng et al. [83] demonstrated that the mean 
carotid-femoral  PWV  (p=0.03),  aortic  augmentation  index 
derived from the radial artery (p=0.002) and carotid augmen-
tation index (p=0.03) were higher in patients with TA com-
pared with controls. 
  In conclusion, the arterial distensibility was assessed by 
automatic carotid-femoral (aortic) PWV measurement using 
the  Complior  Colson  device  was  decreased  in  chronic  in-
flammatory rheumatic diseases. Decrease of arterial disten-
sibility in chronic inflammatory rheumatic diseases are espe-
cially due to inflammation that is triggered by cardiovascular 
risk factors such as hypertension, hyperlipidemia, hypergly-
cemia. In these disorders there is increased risk of develop-
ing premature cardiovascular disease but clear guidelines on 
the management of cardiovascular risk factors is still miss-
ing.  As  inflammation  is  the  basic  pathology  in  these  dis-
eases,  anti-inflammatory  theraphy  would  be  the  main  stay 
treatment strategy for the protection of cardiovascular events 
in the near future. 
ABBREVIATIONS 
(PWV)  =  Pulse wave velocity 
(RA)  =  Rheumatoid arthritis  
(SLE)  =  Systemic lupus erythematosus 
(FMF)  =  Familial Mediterranean fever 
(WG)  =  Wegener’s granulomatosis 
(BD)  =  Behçet’s disease  
(SS)  =  Systemic sclerosis 
(TA)  =  Takayasu's arteritis 
(CRP)  =  C-reactive protein  
(ANCA)  =  Antineutrophil cytoplasmic antibodies  
(aPL)  =  Antiphospholipid antibodies 
(ICAM-1)  =  Intercellular adhesion molecules 1 
(VCAM-1)  =  Vascular cell adhesion molecules 1  
(LDL)  =  Low density lipoprotein 
(ESR)  =  Erythrocyte sedimentation rate 
(TNF)  =  Tumor necrosis factor  
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